Olav Hellebø
Non-executive Director
pharmaceutical
Pharmalink
Spain
Biography
Mr Hellebø is CEO of UK-listed ReNeuron Group plc, and chairman and co-founder of Palma Biotech S.L. in Spain. He is an experienced pharmaceutical executive who has held senior positions in the pharmaceutical industry in both Europe and the USA. Previously Mr Hellebø was CEO of Clavis Pharma ASA and before that he was Senior Vice President, UCB Pharma and President of Immunology Operations. In this position he built and led the global organization responsible for the successful registration and launch of Cimzia®, UCB’s antibody drug for the treatment of rheumatoid arthritis and Crohn’s disease. From 2003 to 2004, Mr Hellebø was Chief Operating Officer of Novartis UK and prior to that held a series of senior international roles at Schering Plough, the last as head of Schering Plough’s Oncology Biotech Division in the USA. Mr Hellebø graduated Summa cum Laude in international business studies from Hofstra University, New York and received an MBA from IESE, Barcelona.
Research Interest
Immunology Operations,Rheumatoid Arthritis and Crohn’s disease
